Long-term cost-effectiveness of pharmacist-managed hypertension care in China

作者：Jingxuan Wei, Lihong Gao, Zhuying Jing, Jia Wang, Yulu Zhu, Haomin Zhu, Xin Li · 发表于：BMC Health Services Research · 年份：2025 · DOI：10.1186/s12913-025-13785-4 · 被引用次数：1 · 研究领域：Pharmaceutical Practices and Patient Outcomes、Healthcare Systems and Reforms、Blood Pressure and Hypertension Studies

BACKGROUND: Hypertension is one of the main causes of cardiovascular and kidney diseases in China. However, the rate of effective blood pressure control remains low. Previous studies have shown pharmacist-managed hypertension care can improve treatment outcomes. Nevertheless, the long-term cost-effectiveness of pharmaceutical care has not been fully evaluated in China. METHODS: This study constructed a Markov model to evaluate the cost-effectiveness of pharmacist-managed hypertension care compared with usual care. The model followed a hypothetical patient cohort using 6-month cycles and extended to their life expectancy, adopting a healthcare system perspective. Model parameters were obtained from a randomized controlled trial and published Chinese population data. The primary outcomes included total costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs). Sensitivity and scenario analyses were conducted to test the robustness of the results. Cumulative medical costs and potential savings from implementing pharmacist-managed hypertension care were estimated. RESULTS: Pharmacist-managed hypertension care increased QALYs by 0.07 per person and increased medical costs by $262.58. The ICER was $3,708 per QALY, which is lower than the accepted willingness-to-pay threshold in China. Pharmacist-managed hypertension care reduced the incidence of cardiovascular and renal events and reduced overall healthcare expenditures in these disease areas. Sc...